Skip to main content
. 2022 Oct 19;128(24):4185–4193. doi: 10.1002/cncr.34498

TABLE 2.

Secondary endpoint: breast‐cancer–related events, by trial arm, after a median follow‐up of 44.1 mo

SAD AD
61 patients 62 patients
N % N %
Ipsilateral breast tumor recurrence 0 0
Contralateral breast cancer 1 1.5 1 1.5
Isolated axillary relapse 1 1.5 0 0
Distant relapse 6 9.2 8 12.3
Death 3 4.6 2 3.1

Abbreviations: AD, axial dissection; IQR, interquartile range; SAD, selective axillary dissection.